C5 and paroxysmal nocturnal hemoglobinuria: From 2011 to 2022, a total of 371 patients met the study eligibility criteria and received treatment for PNH with a C5 inhibitor (induction phase: n = 175; maintenance phase: n = 362) (Supplemental Figure S1).